Literature DB >> 9435307

A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice.

W A Boisvert1, R Santiago, L K Curtiss, R A Terkeltaub.   

Abstract

Chronic macrophage-mediated inflammation is central to atherosclerosis. A role of the monocyte chemotactic and activating C-C chemokine JE/monocyte chemotactic protein-1 has been proposed. However, the human C-X-C chemokines growth-regulated oncogene (GROalpha) and IL-8, and their shared receptor, CXCR-2, also can be expressed at sites of chronic inflammation. Because we detected CXCR-2 in the intima of human atherosclerotic lesions, we examined the role of leukocyte CXCR-2 expression in affecting lesion cellularity. Atherosclerosis-susceptible LDL receptor-deficient mice were irradiated, successfully repopulated with bone marrow cells that either lacked or expressed mIL-8RH (the homologue of CXCR-2), and fed an atherogenic diet for 16 wk. In recipients of mIL-8RH+/+ marrow, mIL-8RH colocalized with densely accumulated intimal MOMA-2 positive macrophages. In contrast, lesions in recipients of mIL-8RH-/- marrow lacked mIL-8RH, had little intimal MOMA-2 staining, and were less extensive. The mIL-8RH ligand KC/GROalpha was detected in the intima of all aortic atherosclerotic lesions. Thus, the capacity of leukocytes to express mIL-8RH, and associated intralesional expression of its ligands such as KC/GROalpha, mediated the intimal accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9435307      PMCID: PMC508574          DOI: 10.1172/JCI1195

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  65 in total

1.  Oxidized LDL potentiates LPS-induced transcription of the chemokine KC gene.

Authors:  T A Hamilton; J A Major
Journal:  J Leukoc Biol       Date:  1996-06       Impact factor: 4.962

2.  Lymphocyte populations in atherosclerotic lesions of apoE -/- and LDL receptor -/- mice. Decreasing density with disease progression.

Authors:  S E Roselaar; P X Kakkanathu; A Daugherty
Journal:  Arterioscler Thromb Vasc Biol       Date:  1996-08       Impact factor: 8.311

3.  Interleukin-8 production by macrophages from atheromatous plaques.

Authors:  J Apostolopoulos; P Davenport; P G Tipping
Journal:  Arterioscler Thromb Vasc Biol       Date:  1996-08       Impact factor: 8.311

4.  Chemokines and T lymphocyte activation: II. Facilitation of human T cell trafficking in severe combined immunodeficiency mice.

Authors:  W J Murphy; Z G Tian; O Asai; S Funakoshi; P Rotter; M Henry; R M Strieter; S L Kunkel; D L Longo; D D Taub
Journal:  J Immunol       Date:  1996-03-15       Impact factor: 5.422

Review 5.  In vivo, in vitro, and molecular aspects of interleukin-8 and the interleukin-8 receptors.

Authors:  R C Hoch; I U Schraufstätter; C G Cochrane
Journal:  J Lab Clin Med       Date:  1996-08

Review 6.  Chemokines: progress toward identifying molecular targets for therapeutic agents.

Authors:  O M Howard; A Ben-Baruch; J J Oppenheim
Journal:  Trends Biotechnol       Date:  1996-02       Impact factor: 19.536

Review 7.  Inflammation as an early component of atherosclerosis and vascular damage--a role for P-selectin and platelet-activating factor.

Authors:  S M Prescott; T M McIntyre; G A Zimmerman; D M Stafforini
Journal:  Jpn Circ J       Date:  1996-03

8.  Monocyte and neutrophil adhesion to matrix proteins is selectively enhanced in the presence of inflammatory mediators.

Authors:  J Lundahl; C M Sköld; G Halldén; M Hallgren; A Eklund
Journal:  Scand J Immunol       Date:  1996-08       Impact factor: 3.487

9.  The CXC chemokines growth-regulated oncogene (GRO) alpha, GRObeta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor.

Authors:  S K Ahuja; P M Murphy
Journal:  J Biol Chem       Date:  1996-08-23       Impact factor: 5.157

10.  The interleukin-8 receptor B and CXC chemokines can mediate transendothelial migration of human skin homing T cells.

Authors:  L F Santamaria Babi; B Moser; M T Perez Soler; R Moser; P Loetscher; B Villiger; K Blaser; C Hauser
Journal:  Eur J Immunol       Date:  1996-09       Impact factor: 5.532

View more
  99 in total

Review 1.  Chemokines in myocardial failure -- pathogenic importance and potential therapeutic targets.

Authors:  P Aukrust; J K Damås; L Gullestad; S S Frøland
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

2.  Chemokines and atherosclerosis: what Adam Smith has to say about vascular disease.

Authors:  B J Rollins
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

Review 3.  Therapeutic implications of chemokine-mediated pathways in atherosclerosis: realistic perspectives and utopias.

Authors:  Stavros Apostolakis; Virginia Amanatidou; Demetrios A Spandidos
Journal:  Acta Pharmacol Sin       Date:  2010-08-16       Impact factor: 6.150

4.  Expression and function of CXCL16 in a novel model of gout.

Authors:  Jeffrey H Ruth; Monica D Arendt; M Asif Amin; Salahuddin Ahmed; Hubert Marotte; Bradley J Rabquer; Charles Lesch; Solhee Lee; Alisa E Koch
Journal:  Arthritis Rheum       Date:  2010-08

5.  TREM-1 is a positive regulator of TNF-α and IL-8 production in U937 foam cells.

Authors:  Yu-Shi Wang; Xiang-Jun Li; Wai-Ou Zhao
Journal:  Bosn J Basic Med Sci       Date:  2012-05       Impact factor: 3.363

6.  Developmental expression of two CXC chemokines, MIP-2 and KC, and their receptors.

Authors:  J Luan; Y Furuta; J Du; A Richmond
Journal:  Cytokine       Date:  2001-06-07       Impact factor: 3.861

7.  Pravastatin suppresses the interleukin-8 production induced by thrombin in human aortic endothelial cells cultured with high glucose by inhibiting the p44/42 mitogen activated protein kinase.

Authors:  M Takata; M Urakaze; R Temaru; K Yamazaki; N Nakamura; Y Nobata; M Kishida; A Sato; M Kobayashi
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

8.  Chemokine receptors CXCR2 and CX3CR1 differentially regulate functional responses of bone-marrow endothelial progenitors during atherosclerotic plaque regression.

Authors:  Oana Herlea-Pana; Longbiao Yao; Janet Heuser-Baker; Qiongxin Wang; Qilong Wang; Constantin Georgescu; Ming-Hui Zou; Jana Barlic-Dicen
Journal:  Cardiovasc Res       Date:  2015-03-12       Impact factor: 10.787

9.  Treatment with Evasin-3 reduces atherosclerotic vulnerability for ischemic stroke, but not brain injury in mice.

Authors:  Jean-Christophe Copin; Rafaela F da Silva; Rodrigo A Fraga-Silva; Luciano Capettini; Silvia Quintao; Sébastien Lenglet; Graziano Pelli; Katia Galan; Fabienne Burger; Vincent Braunersreuther; Karl Schaller; Maud Deruaz; Amanda E Proudfoot; Franco Dallegri; Nikolaos Stergiopulos; Robson A S Santos; Yvan Gasche; François Mach; Fabrizio Montecucco
Journal:  J Cereb Blood Flow Metab       Date:  2012-12-19       Impact factor: 6.200

Review 10.  Regulation of atherogenesis by chemokines and chemokine receptors.

Authors:  Wuzhou Wan; Philip M Murphy
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2012-12-07       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.